Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Gabrielle Gainsborough"'
Autor:
David C. Jackson, Catherine E. Hanratty, Kian Fan Chung, John G. Matthews, Ratko Djukanovic, Maria Nunez, Robert Niven, Douglas S. Robinson, Liam G Heaney, Michelle Bourne, Catherine Borg, Clare Connolly, Mary Bellamy, Val Hudson, Gareth M. Davies, Christopher E. Brightling, Beverley Hargadon, Traceyanne Grandison, Ian M. Adcock, Sebastian L. Johnston, Rekha Chaudhuri, Geraldine Jones, James Lordan, Andrew Menzies-Gow, Adnam Azim, Dominic E. Shaw, John Busby, Ashley Woodcock, Freda Yang, Peter Bradding, Christopher Corrigan, David F. Choy, Cecile T.J. Holweg, Douglas C. Cowan, Paula McCourt, Tim Harrison, Peter H. Howarth, AH Mansur, Joel Solis, Avril Horn, Joseph R. Arron, Gabrielle Gainsborough, Sarah E Davies, Stephen J. Fowler, Roisin Stone, Timothy C. Hardman, Ian D. Pavord, Samantha Walker, Richard W. Costello, Katherine C. Smith
Publikováno v:
The Lancet. Respiratory Medicine
Heaney, L G, Busby, J, Hanratty, C E, Djukanovic, R, Woodcock, A, Walker, S M, Hardman, T C, Arron, J R, Choy, D F, Bradding, P, Brightling, C E, Chaudhuri, R, Cowan, D C, Mansur, A H, Fowler, S J, Niven, R M, Howarth, P H, Lordan, J L, Menzies-Gow, A, Harrison, T W, Robinson, D S, Holweg, C T J, Matthews, J G & Pavord, I D 2020, ' Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial ', The Lancet Respiratory Medicine, vol. 9, no. 1, pp. 57-68 . https://doi.org/10.1016/S2213-2600(20)30397-0
Investigators for the MRC Refractory Asthma Stratification Programme 2020, ' Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma : a multicentre, single-blind, parallel group, randomised controlled trial ', The Lancet. Respiratory medicine, vol. 9, no. 1, pp. 57-68 . https://doi.org/10.1016/S2213-2600(20)30397-0
Heaney, L G, Busby, J, Hanratty, C E, Djukanovic, R, Woodcock, A, Walker, S M, Hardman, T C, Arron, J R, Choy, D F, Bradding, P, Brightling, C E, Chaudhuri, R, Cowan, D C, Mansur, A H, Fowler, S J, Niven, R M, Howarth, P H, Lordan, J L, Menzies-Gow, A, Harrison, T W, Robinson, D S, Holweg, C T J, Matthews, J G & Pavord, I D 2020, ' Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial ', The Lancet Respiratory Medicine, vol. 9, no. 1, pp. 57-68 . https://doi.org/10.1016/S2213-2600(20)30397-0
Investigators for the MRC Refractory Asthma Stratification Programme 2020, ' Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma : a multicentre, single-blind, parallel group, randomised controlled trial ', The Lancet. Respiratory medicine, vol. 9, no. 1, pp. 57-68 . https://doi.org/10.1016/S2213-2600(20)30397-0
Background: Asthma treatment guidelines recommend increasing corticosteroid dose to control symptoms and reduce exacerbations. This approach is potentially flawed because symptomatic asthma can occur without corticosteroid responsive type-2 (T2)-driv
Autor:
John Busby, Timothy C. Hardman, Gabrielle Gainsborough, Nazanin Zounemat Kermani, Yike Guo, Liam G Heaney, Ian M. Adcock, Ioannis Pandis, Kai Sun
Publikováno v:
Monitoring airway disease.